β
Outcome MeasureOther

BSI

Brief Symptom Inventory

2 Papers in Blossom

Clinical Thresholds

0212
Non-clinical
Score 0–62
Clinical
Score 63–212

Outcome Data Across Studies

Reported results for BSI across 2 studies with quantitative data.

Outcome data across 8 study arm–timepoint observations
SD
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
2016Secondary
Low then high(experimental)025—Δ——
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer
2016Secondary
High then low(experimental)026—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)014—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)114—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)714—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)1414—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)3014—Δ——
Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression
2025Secondary
DMT inhalation(experimental)9014—Δ——

Papers Using BSI

Paywallindividual

Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression

This open-label fixed-order dose-escalation trial (n=14) evaluated inhaled DMT (15mg & 60mg) for treatment-resistant depression (TRD) for the first time. Results showed rapid and sustained antidepressant effects with a 21-point reduction on the Montgomery-Asberg Depression Rating Scale by day 7 (p<0.001), an 86% response rate, and a 57% remission rate lasting up to 3 months, with significant decreases in suicidal ideation (SI).

Published
Journal
Neuropsychopharmacology
Authors
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., Florence-Vilela, R., Almeida, R., Macedo, R. K. A., Arichelle, F., Pantrigo, E. J., Costa-Macedo, J. V., da Cruz Nunes, J. A., Araújo, D. B., de Araujo Costa Neto, L. A., Nunes Ferreira, L. F., Dantas Correa, L., da Costa Bezerra, R. B., Arcoverde, E., Galvão-Coelho, N. L.
Open Accessindividual

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer

In a randomized, double‑blind, crossover trial of 51 patients with life‑threatening cancer, a single high dose of psilocybin produced large, rapid and sustained reductions in clinician- and self-rated depression and anxiety and increased quality of life, meaning and optimism, with about 80% of participants showing clinically significant improvement at six months. The therapeutic effects were mediated by the intensity of mystical‑type experiences during the session and were corroborated by community observer ratings.

Published
Journal
Journal of Psychopharmacology
Authors
Griffiths, R. R., Johnson, M. W.

Quick Facts

Full Name
Brief Symptom Inventory
Domain
Other
Papers Indexed
2
Score Range
0–212
Interpretation
Lower = better
All Measures